Zheng, Jinping
Baldi, Simonetta
Zhao, Li
Li, Huiping
Lee, Kwan-Ho
Singh, Dave
Papi, Alberto
Grapin, Frédérique
Guasconi, Alessandro
Georges, George http://orcid.org/0000-0002-0303-2273
Funding for this research was provided by:
Chiesi Farmaceutici
Article History
Received: 26 January 2021
Accepted: 11 March 2021
First Online: 23 March 2021
Declarations
:
: The study was approved by the independent ethics committees at each institution. All patients provided written informed consent prior to any study-related procedure.
: Not applicable.
: JZ has no relevant conflicts to disclose. LZ has no relevant conflicts to disclose. HL has no relevant conflicts to disclose. K-HL has no relevant conflicts to disclose. DS reports personal fees from Chiesi during the conduct of the study. Outside the submitted work, he reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Theravance, and Verona. AP reports grants, personal fees, non-financial support and payment for advisory board membership, consultancy, payment for lectures, grants for research, and travel expenses reimbursement from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma and TEVA, and personal fees and non-financial support from Menarini, Novartis, Zambon and Sanofi, all outside the submitted work. SB, FG, AG and GG are employees of Chiesi, the sponsor of the study.